Skip to main content
Top
Published in: Drugs & Aging 2/2005

01-02-2005 | Review Article

Disease-Modifying Therapies for Osteoarthritis

Current Status

Authors: Marc Fajardo, Dr Paul E. Di Cesare

Published in: Drugs & Aging | Issue 2/2005

Login to get access

Abstract

Osteoarthritis, the most common form of arthritis, is a debilitating progressive disease principally affecting the elderly. Osteoarthritis therapy has evolved in the past few decades from symptomatic treatment to possible disease-modifying solutions. In this paper, the pathophysiology of osteoarthritis is first reviewed, including an examination of the mechanisms underlying osteoarthritis and discussions of the roles of cartilage, synovial fluid and subchondral bone. The remainder of the paper discusses therapeutic approaches in current use and those in development, with special attention given to pharmacological treatments. Current approaches to treating osteoarthritis — i.e. medications; nonpharmacological modalities, such as physical therapy, exercise, weight management and orthotics; and (as a last resort) surgery — focus on reducing pain and improving (or at least maintaining) mobility. Drugs currently used to treat osteoarthritis fall into several categories: analgesics, NSAIDs, cyclo-oxygenase-2 (COX-2) inhibitors, corticosteroids, viscosupplementation, and symptomatic slow-acting drugs (‘nutraceuticals’). The analgesics (paracetamol [acetaminophen] and opiates) have demonstrated less symptomatic efficacy than NSAIDs, while the latter have displayed mixed results in terms of joint space narrowing. COX-2 inhibitors have been demonstrated to be equal to or superior to NSAIDs in effectiveness. However, once considered a safer alternative, COX-2 inhibitors have become the subject of intense scrutiny since recent clinical evidence has cast suspicion on their cardiovascular safety profile. Injectable therapies, such as corticosteroids and viscosupplementation have elicited favorable short-term response but no long-term structural modification. On the other hand, the slow-acting drugs, especially chondroitin and glucosamine sulfate, have shown promising results. Also reviewed are other established and experimental therapies that seek to modify and/or even reverse the course of osteoarthritis. These include such medications as colchicine, bisphosphonates and hormones; dietary therapeutics, such as ginger extract and green tea; and such truly experimental treatments as matrix metalloproteinase inhibitors, cytokines, nitric oxide, growth factors and gene therapy. Osteoarthritis continues to be a difficult disorder to treat, as there is no cure as such and current treatments focus mainly on relieving pain and maintaining joint function. The search nevertheless continues for management regimens that can slow, alter or reverse the degenerative processes of osteoarthritis.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
2.
go back to reference Yelin E. The economics of osteoarthritis. In: Brandt K, Doherty M, Lohmander LS, editors. Osteoarthritis. New York: Oxford University Press, 1998: 23–30 Yelin E. The economics of osteoarthritis. In: Brandt K, Doherty M, Lohmander LS, editors. Osteoarthritis. New York: Oxford University Press, 1998: 23–30
3.
go back to reference Di Cesare PE, Abramson SB. Pathogenesis of Osteoarthritis. In: Harris ED, editor. Kelley’s textbook of rheumatology. 7th ed. Philadelphia (PA): Elsevier Science Publisher, 2003: 1493–513 Di Cesare PE, Abramson SB. Pathogenesis of Osteoarthritis. In: Harris ED, editor. Kelley’s textbook of rheumatology. 7th ed. Philadelphia (PA): Elsevier Science Publisher, 2003: 1493–513
4.
5.
go back to reference Linn FC, Radin EL. Lubrication of animal joints: 3. The effect of certain chemical alterations of the cartilage and lubricant. Arthritis Rheum 1968; 11(5): 674–82PubMedCrossRef Linn FC, Radin EL. Lubrication of animal joints: 3. The effect of certain chemical alterations of the cartilage and lubricant. Arthritis Rheum 1968; 11(5): 674–82PubMedCrossRef
6.
go back to reference Dieppe P. The classification and diagnosis of osteoarthritis. In: Kuettner K, Goldberg V, editors. Osteoarthritic Disorders. Rosemont (IL): American Academy of Orthopaedic Surgeons, 1995 Dieppe P. The classification and diagnosis of osteoarthritis. In: Kuettner K, Goldberg V, editors. Osteoarthritic Disorders. Rosemont (IL): American Academy of Orthopaedic Surgeons, 1995
7.
go back to reference Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989; 16(4): 427–41PubMed Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989; 16(4): 427–41PubMed
8.
go back to reference Martin JA, Buckwalter JA. Articular cartilage aging and degeneration. Sports Med Arthroscop Rev 1996; 4: 263–75CrossRef Martin JA, Buckwalter JA. Articular cartilage aging and degeneration. Sports Med Arthroscop Rev 1996; 4: 263–75CrossRef
9.
go back to reference Pelletier JP Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. Baltimore (MD): Williams and Wilkins, 2001: 2195–45 Pelletier JP Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. Baltimore (MD): Williams and Wilkins, 2001: 2195–45
10.
go back to reference Murphy G, Docherty AJP. Molecular studies on the connective tissue metalloproteinases and their inhibitor TIMP. In: Glauert AM, editor. The control of tissue damage. Oxford: Oxford Press, 1988 Murphy G, Docherty AJP. Molecular studies on the connective tissue metalloproteinases and their inhibitor TIMP. In: Glauert AM, editor. The control of tissue damage. Oxford: Oxford Press, 1988
11.
go back to reference Dean DD, Woessner Jr JF. Extracts of human articular cartilage contain an inhibitor of tissue metalloproteinases. Biochem J 1984; 218(1): 277–80PubMed Dean DD, Woessner Jr JF. Extracts of human articular cartilage contain an inhibitor of tissue metalloproteinases. Biochem J 1984; 218(1): 277–80PubMed
12.
go back to reference Yamada H, Stephens RW, Nakagawa T, et al. Human articular cartilage contains an inhibitor of plasminogen activator. J Rheumatol 1988; 15(7): 1138–43PubMed Yamada H, Stephens RW, Nakagawa T, et al. Human articular cartilage contains an inhibitor of plasminogen activator. J Rheumatol 1988; 15(7): 1138–43PubMed
13.
go back to reference Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl 1993; 39: 3–9PubMed Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl 1993; 39: 3–9PubMed
14.
go back to reference Uthman I, Raynauld JP, Haraoui B. Intra-articular therapy in osteoarthritis. Postgrad Med J 2003; 79(934): 449–53PubMedCrossRef Uthman I, Raynauld JP, Haraoui B. Intra-articular therapy in osteoarthritis. Postgrad Med J 2003; 79(934): 449–53PubMedCrossRef
15.
go back to reference Altman D. Laboratory findings in osteoarthritis. In: Moskowitz R, Goldberg V, Mankin J, editors. Osteoarthritis-diagnosis and medical surgical management. Philadelphia (PA): WB Saunders, 1992: 313–328 Altman D. Laboratory findings in osteoarthritis. In: Moskowitz R, Goldberg V, Mankin J, editors. Osteoarthritis-diagnosis and medical surgical management. Philadelphia (PA): WB Saunders, 1992: 313–328
16.
17.
go back to reference Guermazi A, Zaim S, Taouli B, et al. MR findings in knee osteoarthritis. Eur Radiol 2003; 13(6): 1370–86PubMedCrossRef Guermazi A, Zaim S, Taouli B, et al. MR findings in knee osteoarthritis. Eur Radiol 2003; 13(6): 1370–86PubMedCrossRef
18.
go back to reference Lajeunesse D. The role of bone in the treatment of osteoarthritis (1). Osteoarthritis Cartilage 2004; 12Suppl. A: 34–8CrossRef Lajeunesse D. The role of bone in the treatment of osteoarthritis (1). Osteoarthritis Cartilage 2004; 12Suppl. A: 34–8CrossRef
19.
go back to reference Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43(9): 1905–15 Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43(9): 1905–15
20.
go back to reference Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000; 59(12): 936–44PubMedCrossRef Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000; 59(12): 936–44PubMedCrossRef
21.
go back to reference Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62(12): 1145–55PubMedCrossRef Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62(12): 1145–55PubMedCrossRef
22.
go back to reference Hochberg MC, Altman RD, Brandt K, et al. Guidelines for the medical management of osteoarthritis: Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995; 38(11): 1541–6PubMedCrossRef Hochberg MC, Altman RD, Brandt K, et al. Guidelines for the medical management of osteoarthritis: Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995; 38(11): 1541–6PubMedCrossRef
23.
go back to reference Superio-Cabuslay E, Ward MM, Lorig KR. Patient education interventions in osteoarthritis and rheumatoid arthritis: a meta-analytic comparison with nonsteroidal antiinflammatory drug treatment. Arthritis Care Res 1996; 9(4): 292–301PubMedCrossRef Superio-Cabuslay E, Ward MM, Lorig KR. Patient education interventions in osteoarthritis and rheumatoid arthritis: a meta-analytic comparison with nonsteroidal antiinflammatory drug treatment. Arthritis Care Res 1996; 9(4): 292–301PubMedCrossRef
24.
go back to reference Fransen M, Crosbie J, Edmonds J. Physical therapy is effective for patients with osteoarthritis of the knee: a randomized controlled clinical trial. J Rheumatol 2001; 28(1): 156–64PubMed Fransen M, Crosbie J, Edmonds J. Physical therapy is effective for patients with osteoarthritis of the knee: a randomized controlled clinical trial. J Rheumatol 2001; 28(1): 156–64PubMed
25.
go back to reference Toda Y. The effect of energy restriction, walking, and exercise on lower extremity lean body mass in obese women with osteoarthritis of the knee. J Orthop Sci 2001; 6(2): 148–54PubMedCrossRef Toda Y. The effect of energy restriction, walking, and exercise on lower extremity lean body mass in obese women with osteoarthritis of the knee. J Orthop Sci 2001; 6(2): 148–54PubMedCrossRef
26.
go back to reference Huang MH, Chen CH, Chen TW, et al. The effects of weight reduction on the rehabilitation of patients with knee osteoarthritis and obesity. Arthritis Care Res 2000; 13(6): 398–405PubMedCrossRef Huang MH, Chen CH, Chen TW, et al. The effects of weight reduction on the rehabilitation of patients with knee osteoarthritis and obesity. Arthritis Care Res 2000; 13(6): 398–405PubMedCrossRef
27.
go back to reference Toda Y, Toda T, Takemura S, et al. Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief of obese patients with knee osteoarthritis after a weight control program. J Rheumatol 1998; 25(11): 2181–6PubMed Toda Y, Toda T, Takemura S, et al. Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief of obese patients with knee osteoarthritis after a weight control program. J Rheumatol 1998; 25(11): 2181–6PubMed
28.
go back to reference Messier SP, Loeser RF, Miller GD, et al. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum 2004; 50(5): 1501–10PubMedCrossRef Messier SP, Loeser RF, Miller GD, et al. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum 2004; 50(5): 1501–10PubMedCrossRef
29.
go back to reference Kerrigan DC, Lelas JL, Goggins J, et al. Effectiveness of a lateral-wedge insole on knee varus torque in patients with knee osteoarthritis. Arch Phys Med Rehabil 2002; 83(7): 889–93PubMedCrossRef Kerrigan DC, Lelas JL, Goggins J, et al. Effectiveness of a lateral-wedge insole on knee varus torque in patients with knee osteoarthritis. Arch Phys Med Rehabil 2002; 83(7): 889–93PubMedCrossRef
30.
go back to reference Toda Y, Tsukimura N, Kato A. The effects of different elevations of laterally wedged insoles with subtalar strapping on medial compartment osteoarthritis of the knee. Arch Phys Med Rehabil 2004; 85(4): 673–7PubMedCrossRef Toda Y, Tsukimura N, Kato A. The effects of different elevations of laterally wedged insoles with subtalar strapping on medial compartment osteoarthritis of the knee. Arch Phys Med Rehabil 2004; 85(4): 673–7PubMedCrossRef
31.
go back to reference The management of chronic pain in older persons. AGS Panel on Chronic Pain in Older Persons. American Geriatrics Society. Geriatrics 1998; 53Suppl. 3: S8–24 The management of chronic pain in older persons. AGS Panel on Chronic Pain in Older Persons. American Geriatrics Society. Geriatrics 1998; 53Suppl. 3: S8–24
32.
go back to reference Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003; 163(2): 169–78PubMedCrossRef Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003; 163(2): 169–78PubMedCrossRef
33.
go back to reference Pincus T, Koch GG, Sokka T, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001; 44(7): 1587–98PubMedCrossRef Pincus T, Koch GG, Sokka T, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001; 44(7): 1587–98PubMedCrossRef
34.
go back to reference Peloso PM, Bellamy N, Bensen W, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 2000; 27(3): 764–71PubMed Peloso PM, Bellamy N, Bensen W, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 2000; 27(3): 764–71PubMed
35.
go back to reference Ottillinger B, Gomor B, Michel BA, et al. Efficacy and safety of eltenac gel in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 2001; 9(3): 273–80PubMedCrossRef Ottillinger B, Gomor B, Michel BA, et al. Efficacy and safety of eltenac gel in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 2001; 9(3): 273–80PubMedCrossRef
36.
go back to reference Huskisson EC, Berry H, Gishen P, et al. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis. J Rheumatol 1995; 22(10): 1941–6PubMed Huskisson EC, Berry H, Gishen P, et al. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis. J Rheumatol 1995; 22(10): 1941–6PubMed
37.
go back to reference van Kuijk C, Cheng X, Hottya G, et al. The effects of rofecoxib and diclofenac on knee osteoarthritis articular cartilage: the results from one-year prospective clinical trials. Arthritis Rheum 2000; 43: s220–924 van Kuijk C, Cheng X, Hottya G, et al. The effects of rofecoxib and diclofenac on knee osteoarthritis articular cartilage: the results from one-year prospective clinical trials. Arthritis Rheum 2000; 43: s220–924
38.
go back to reference Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000; 160(12): 1781–7PubMedCrossRef Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000; 160(12): 1781–7PubMedCrossRef
39.
go back to reference Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002; 287(1): 64–71PubMedCrossRef Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002; 287(1): 64–71PubMedCrossRef
40.
go back to reference Gibofsky A, Williams GW, McKenna F, et al. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum 2003; 48(11): 3102–11PubMedCrossRef Gibofsky A, Williams GW, McKenna F, et al. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum 2003; 48(11): 3102–11PubMedCrossRef
41.
go back to reference Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003; 48(2): 370–7PubMedCrossRef Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003; 48(2): 370–7PubMedCrossRef
42.
go back to reference Ravaud P, Moulinier L, Giraudeau B, et al. Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial. Arthritis Rheum 1999; 42(3): 475–82PubMedCrossRef Ravaud P, Moulinier L, Giraudeau B, et al. Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial. Arthritis Rheum 1999; 42(3): 475–82PubMedCrossRef
43.
go back to reference Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998; 25(11): 2203–12PubMed Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998; 25(11): 2203–12PubMed
44.
go back to reference Lo GH, LaValley M, McAlindon T, et al. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2003; 290(23): 3115–21PubMedCrossRef Lo GH, LaValley M, McAlindon T, et al. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2003; 290(23): 3115–21PubMedCrossRef
45.
go back to reference Towheed TE, Anastassiades TP, Shea B, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2001; (1): CD002946 Towheed TE, Anastassiades TP, Shea B, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2001; (1): CD002946
46.
go back to reference Leeb BF, Schweitzer H, Montag K, et al. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27(1): 205–11PubMed Leeb BF, Schweitzer H, Montag K, et al. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27(1): 205–11PubMed
47.
go back to reference Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163(13): 1514–22PubMedCrossRef Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163(13): 1514–22PubMedCrossRef
48.
go back to reference McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283(11): 1469–75PubMedCrossRef McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283(11): 1469–75PubMedCrossRef
49.
go back to reference Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial: evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum 2001; 44(11): 2539–47PubMedCrossRef Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial: evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum 2001; 44(11): 2539–47PubMedCrossRef
50.
go back to reference Pelletier JP, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum 2000; 43(10): 2339–48PubMedCrossRef Pelletier JP, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum 2000; 43(10): 2339–48PubMedCrossRef
51.
go back to reference Das SK, Ramakrishnan S, Mishra K, et al. A randomized controlled trial to evaluate the slow-acting symptom-modifying effects of colchicine in osteoarthritis of the knee: a preliminary report. Arthritis Rheum 2002; 47(3): 280–4PubMedCrossRef Das SK, Ramakrishnan S, Mishra K, et al. A randomized controlled trial to evaluate the slow-acting symptom-modifying effects of colchicine in osteoarthritis of the knee: a preliminary report. Arthritis Rheum 2002; 47(3): 280–4PubMedCrossRef
52.
go back to reference Nevitt MC, Felson DT, Williams EN, et al. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2001; 44(4): 811–8PubMedCrossRef Nevitt MC, Felson DT, Williams EN, et al. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2001; 44(4): 811–8PubMedCrossRef
53.
go back to reference Bliddal H, Rosetzsky A, Schlichting P, et al. A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis Cartilage 2000; 8(1): 9–12PubMedCrossRef Bliddal H, Rosetzsky A, Schlichting P, et al. A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis Cartilage 2000; 8(1): 9–12PubMedCrossRef
55.
go back to reference Spector TD, Conaghan P, Buckland-Wright JC, et al. Risedronate produces disease modification and symptomatic benefit in the treatment of knee osteoarthritis: results from the BRISK Study [abstract SLB20]. 67th Annual Scientific Meeting of American College of Rheumatology; 2003 Oct 23–28; Orlando Spector TD, Conaghan P, Buckland-Wright JC, et al. Risedronate produces disease modification and symptomatic benefit in the treatment of knee osteoarthritis: results from the BRISK Study [abstract SLB20]. 67th Annual Scientific Meeting of American College of Rheumatology; 2003 Oct 23–28; Orlando
56.
go back to reference Caldwell JR, Offenberg HL, Ramanathan-Girish S, et al. A safety, tolerability and pharmaco-kinetic study of intra-articular recombinant human insulin-like growth factor 1 (rhIGF-1) in patients with severe osteoarthritis of the knee. Arthritis Rheum 2000; 43: s223–941 Caldwell JR, Offenberg HL, Ramanathan-Girish S, et al. A safety, tolerability and pharmaco-kinetic study of intra-articular recombinant human insulin-like growth factor 1 (rhIGF-1) in patients with severe osteoarthritis of the knee. Arthritis Rheum 2000; 43: s223–941
57.
go back to reference Goupille P, Giraubeau B, Conrozier T, et al. Safety and efficacy of intra-articular injection of IL-1ra (IL-1 receptor antagonist) in patients with painful osteoarthritis of the knee: a multicenter, double blind study [abstract 1822]. Arthritis Rheum 2003; 48 (suppl): S696 Goupille P, Giraubeau B, Conrozier T, et al. Safety and efficacy of intra-articular injection of IL-1ra (IL-1 receptor antagonist) in patients with painful osteoarthritis of the knee: a multicenter, double blind study [abstract 1822]. Arthritis Rheum 2003; 48 (suppl): S696
58.
go back to reference Bradley JD, Brandt KD, Katz BP, et al. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991; 325(2): 87–91PubMedCrossRef Bradley JD, Brandt KD, Katz BP, et al. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991; 325(2): 87–91PubMedCrossRef
59.
go back to reference Bradley JD, Brandt KD, Katz BP, et al. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. J Rheumatol 1992; 19(12): 1950–4PubMed Bradley JD, Brandt KD, Katz BP, et al. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. J Rheumatol 1992; 19(12): 1950–4PubMed
60.
go back to reference Amadio Jr P. Peripherally acting analgesics. Am J Med 1984; 77(3A): 17–26PubMed Amadio Jr P. Peripherally acting analgesics. Am J Med 1984; 77(3A): 17–26PubMed
61.
go back to reference Altman R, Howell DS. Disease modifying osteoarthritis drugs. In: LL Brandt K, editor. Osteoarthritis. Oxford: Oxford University Press, 1998: 417–428 Altman R, Howell DS. Disease modifying osteoarthritis drugs. In: LL Brandt K, editor. Osteoarthritis. Oxford: Oxford University Press, 1998: 417–428
62.
go back to reference Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000; 43(2): 378–85PubMedCrossRef Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000; 43(2): 378–85PubMedCrossRef
63.
go back to reference Towheed TE. Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip. Journal of Rheumatology 1997; 24(2): 349–57PubMed Towheed TE. Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip. Journal of Rheumatology 1997; 24(2): 349–57PubMed
64.
go back to reference Tramer MR, Moore RA, Reynolds DJ, et al. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998; 316(7128): 333–8PubMedCrossRef Tramer MR, Moore RA, Reynolds DJ, et al. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998; 316(7128): 333–8PubMedCrossRef
65.
go back to reference Scheiman JM. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med 2002; 69Suppl. 1: SI40–6PubMedCrossRef Scheiman JM. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med 2002; 69Suppl. 1: SI40–6PubMedCrossRef
66.
go back to reference McKenna F, Borenstein D, Wendt H, et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001; 30(1): 11–8PubMedCrossRef McKenna F, Borenstein D, Wendt H, et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001; 30(1): 11–8PubMedCrossRef
67.
go back to reference Fitzgerald G. Coxibs and cardiovascular disease. New Engl J Med 2004; 351(17): 1710–1CrossRef Fitzgerald G. Coxibs and cardiovascular disease. New Engl J Med 2004; 351(17): 1710–1CrossRef
68.
go back to reference Menkes CJ. Intraarticular treatment of osteoarthritis and guidelines to its assessment. J Rheumatol Suppl 1994; 41: 74–6PubMed Menkes CJ. Intraarticular treatment of osteoarthritis and guidelines to its assessment. J Rheumatol Suppl 1994; 41: 74–6PubMed
69.
go back to reference Creamer P. Intra-articular corticosteroid treatment in osteoarthritis. Curr Opin Rheumatol 1999; 11(5): 417–21PubMedCrossRef Creamer P. Intra-articular corticosteroid treatment in osteoarthritis. Curr Opin Rheumatol 1999; 11(5): 417–21PubMedCrossRef
70.
go back to reference Wilder R. Corticosteroids. In: Klippel J, editor. Primer on the rheumatic diseases. Atlanta (GA): The Arthritis Foundation, 1997: 427–431 Wilder R. Corticosteroids. In: Klippel J, editor. Primer on the rheumatic diseases. Atlanta (GA): The Arthritis Foundation, 1997: 427–431
71.
go back to reference DiBattista JA, Martel-Pelletier, Wosu LO, et al. Glucocorticoid receptor mediated inhibition of interleukin-1 stimulated neutral metalloprotease synthesis in normal human chondrocytes. J Clin Endocrinol Metab 1991; 72(2): 316–26PubMedCrossRef DiBattista JA, Martel-Pelletier, Wosu LO, et al. Glucocorticoid receptor mediated inhibition of interleukin-1 stimulated neutral metalloprotease synthesis in normal human chondrocytes. J Clin Endocrinol Metab 1991; 72(2): 316–26PubMedCrossRef
72.
go back to reference Gaffney K, Ledingham J, Perry JD. Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response. Ann Rheum Dis 1995; 54(5): 379–81PubMedCrossRef Gaffney K, Ledingham J, Perry JD. Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response. Ann Rheum Dis 1995; 54(5): 379–81PubMedCrossRef
73.
go back to reference Jones A, Regan M, Ledingham J, et al. Importance of placement of intra-articular steroid injections. BMJ 1993; 307(6915): 1329–30PubMedCrossRef Jones A, Regan M, Ledingham J, et al. Importance of placement of intra-articular steroid injections. BMJ 1993; 307(6915): 1329–30PubMedCrossRef
74.
go back to reference Balch HW, Gibson JM, El-Ghobarey AF, et al. Repeated corticosteroid injections into knee joints. Rheumatol Rehabil 1977; 16(3): 137–40PubMedCrossRef Balch HW, Gibson JM, El-Ghobarey AF, et al. Repeated corticosteroid injections into knee joints. Rheumatol Rehabil 1977; 16(3): 137–40PubMedCrossRef
75.
go back to reference Dieppe P, Sathapatayavongs B, Jones HE, et al. Intra-articular steroids in osteoarthritis. Rheumatol Rehabil 1980; 19(4): 212–7PubMedCrossRef Dieppe P, Sathapatayavongs B, Jones HE, et al. Intra-articular steroids in osteoarthritis. Rheumatol Rehabil 1980; 19(4): 212–7PubMedCrossRef
76.
go back to reference Brandt KD, Smith Jr GN, Simon LS. Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? Arthritis Rheum 2000; 43(6): 1192–203PubMedCrossRef Brandt KD, Smith Jr GN, Simon LS. Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? Arthritis Rheum 2000; 43(6): 1192–203PubMedCrossRef
77.
go back to reference Kirwan JR, Rankin E. Intra-articular therapy in osteoarthritis. Baillieres Clin Rheumatol 1997; 11(4): 769–94PubMedCrossRef Kirwan JR, Rankin E. Intra-articular therapy in osteoarthritis. Baillieres Clin Rheumatol 1997; 11(4): 769–94PubMedCrossRef
78.
go back to reference Peyron JG. A new approach to the treatment of osteoarthritis: viscosupplementation. Osteoarthritis Cartilage 1993; 1(2): 85–7PubMedCrossRef Peyron JG. A new approach to the treatment of osteoarthritis: viscosupplementation. Osteoarthritis Cartilage 1993; 1(2): 85–7PubMedCrossRef
79.
go back to reference Dougados M, Nguyen M, Listrat V, et al. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage 1993; 1(2): 97–103PubMedCrossRef Dougados M, Nguyen M, Listrat V, et al. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage 1993; 1(2): 97–103PubMedCrossRef
80.
go back to reference Leardini G, Mattara L, Franceschini M, et al. Intra-articular treatment of knee osteoarthritis: a comparative study between hyaluronic acid and 6-methyl prednisolone acetate. Clin Exp Rheumatol 1991; 9(4): 375–81PubMed Leardini G, Mattara L, Franceschini M, et al. Intra-articular treatment of knee osteoarthritis: a comparative study between hyaluronic acid and 6-methyl prednisolone acetate. Clin Exp Rheumatol 1991; 9(4): 375–81PubMed
81.
go back to reference Jones AC, Pattrick M, Doherty S, et al. Intra-articular hyaluronic acid compared to intra-articular triamcinolone hexacetonide in inflammatory knee osteoarthritis. Osteoarthritis Cartilage 1995; 3(4): 269–73PubMedCrossRef Jones AC, Pattrick M, Doherty S, et al. Intra-articular hyaluronic acid compared to intra-articular triamcinolone hexacetonide in inflammatory knee osteoarthritis. Osteoarthritis Cartilage 1995; 3(4): 269–73PubMedCrossRef
82.
go back to reference Maheu E. Hyaluronan in knee osteoarthritis: a review of the clinical trials with Hyalgan. Eur J Rheumatol Inflamm 1995; 15: 17–24 Maheu E. Hyaluronan in knee osteoarthritis: a review of the clinical trials with Hyalgan. Eur J Rheumatol Inflamm 1995; 15: 17–24
83.
go back to reference Raynauld JP, Torrance GW, Band PA, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002; 10(7): 506–17PubMedCrossRef Raynauld JP, Torrance GW, Band PA, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002; 10(7): 506–17PubMedCrossRef
84.
go back to reference Felson DT. Hyaluronate sodium injections for osteoarthritis: hope, hype, and hard truths. Arch Intern Med 2002; 162: 245–7PubMedCrossRef Felson DT. Hyaluronate sodium injections for osteoarthritis: hope, hype, and hard truths. Arch Intern Med 2002; 162: 245–7PubMedCrossRef
85.
go back to reference Puhl W, Bernau A, Greiling H, et al. Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter double blind study. Osteoarthritis Cartilage 1993; 1(4): 233–41PubMedCrossRef Puhl W, Bernau A, Greiling H, et al. Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter double blind study. Osteoarthritis Cartilage 1993; 1(4): 233–41PubMedCrossRef
86.
go back to reference Lohmander LS, Dalen N, Englund G, et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Ann Rheum Dis 1996; 55(7): 424–31PubMedCrossRef Lohmander LS, Dalen N, Englund G, et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Ann Rheum Dis 1996; 55(7): 424–31PubMedCrossRef
87.
go back to reference Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis: the role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am 1999; 25(2): 379–95PubMedCrossRef Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis: the role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am 1999; 25(2): 379–95PubMedCrossRef
88.
go back to reference Johnson KA, Hulse DA, Hart RC, et al. Effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection model of osteoarthritis. Osteoarthritis Cartilage 2001; 9(1): 14–21PubMedCrossRef Johnson KA, Hulse DA, Hart RC, et al. Effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection model of osteoarthritis. Osteoarthritis Cartilage 2001; 9(1): 14–21PubMedCrossRef
89.
go back to reference Cordoba F, Nimni ME. Chondroitin sulfate and other sulfate containing chondroprotective agents may exhibit their effects by overcoming a deficiency of sulfur amino acids. Osteoarthritis Cartilage 2003; 11(3): 228–30PubMedCrossRef Cordoba F, Nimni ME. Chondroitin sulfate and other sulfate containing chondroprotective agents may exhibit their effects by overcoming a deficiency of sulfur amino acids. Osteoarthritis Cartilage 2003; 11(3): 228–30PubMedCrossRef
90.
go back to reference Mauviel A, Loyau G, Pujol JP, et al. Effects of unsaponifiable extracts of avocado/soy beans (PIAS) on the production of collagen by cultures of synoviocytes, articular chondrocytes and skin fibroblasts [in French]. Rev Rhum Mal Osteoartic 1989; 56(2): 207–11PubMed Mauviel A, Loyau G, Pujol JP, et al. Effects of unsaponifiable extracts of avocado/soy beans (PIAS) on the production of collagen by cultures of synoviocytes, articular chondrocytes and skin fibroblasts [in French]. Rev Rhum Mal Osteoartic 1989; 56(2): 207–11PubMed
91.
go back to reference Molist A, Romaris M, Lindahl U, et al. Changes in glycosami-noglycan structure and composition of the main heparan sulphate proteoglycan from human colon carcinoma cells (perlecan) during cell differentiation. Eur J Biochem 1998; 254(2): 371–7PubMedCrossRef Molist A, Romaris M, Lindahl U, et al. Changes in glycosami-noglycan structure and composition of the main heparan sulphate proteoglycan from human colon carcinoma cells (perlecan) during cell differentiation. Eur J Biochem 1998; 254(2): 371–7PubMedCrossRef
92.
go back to reference Adebowale AO, Cox DS, Liang Z, et al. Analysis of glucosamine and chondroitin sulfate content in marked products and the caco-2 permeability of chondroitin sulfate raw materials. J Am Nutraceutical Assoc (JANA) 2000; 3: 37–44 Adebowale AO, Cox DS, Liang Z, et al. Analysis of glucosamine and chondroitin sulfate content in marked products and the caco-2 permeability of chondroitin sulfate raw materials. J Am Nutraceutical Assoc (JANA) 2000; 3: 37–44
93.
go back to reference Rindone JP, Hiller D, Collacott E, et al. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000; 172(2): 91–4PubMedCrossRef Rindone JP, Hiller D, Collacott E, et al. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000; 172(2): 91–4PubMedCrossRef
94.
go back to reference Florent F, Richy Y, Bruyere O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin sulfate in osteoarthritis: a comprehensive meta-analysis. Washington, DC: ACR, 2003 Florent F, Richy Y, Bruyere O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin sulfate in osteoarthritis: a comprehensive meta-analysis. Washington, DC: ACR, 2003
95.
go back to reference NIH studying dietary supplements for arthritis. Mayo Clin Health Lett 2000; 18(8): 4 NIH studying dietary supplements for arthritis. Mayo Clin Health Lett 2000; 18(8): 4
96.
go back to reference Henrotin YE, Sanchez C, Deberg MA, et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol 2003; 30(8): 1825–34PubMed Henrotin YE, Sanchez C, Deberg MA, et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol 2003; 30(8): 1825–34PubMed
97.
go back to reference Ernst E. Avocado-soybean unsaponifiables (ASU) for osteoarthritis: a systematic review. Clin Rheumatol 2003; 22(4–5): 285–8PubMedCrossRef Ernst E. Avocado-soybean unsaponifiables (ASU) for osteoarthritis: a systematic review. Clin Rheumatol 2003; 22(4–5): 285–8PubMedCrossRef
98.
go back to reference Mycek M, Harvey R, Champe P. Pharmacology. 2nd ed. In: Harvey CP, editor. Lippincott’s illustrated reviews. New York: Lippincott, 2000 Mycek M, Harvey R, Champe P. Pharmacology. 2nd ed. In: Harvey CP, editor. Lippincott’s illustrated reviews. New York: Lippincott, 2000
99.
go back to reference Katiyar SK, Mukhtar H. Tea consumption and cancer. World Rev Nutr Diet 1996; 79: 154–84PubMed Katiyar SK, Mukhtar H. Tea consumption and cancer. World Rev Nutr Diet 1996; 79: 154–84PubMed
100.
go back to reference Haqqi TM, Anthony DD, Gupta S, et al. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci U S A 1999; 96(8): 4524–9PubMedCrossRef Haqqi TM, Anthony DD, Gupta S, et al. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci U S A 1999; 96(8): 4524–9PubMedCrossRef
101.
go back to reference Singh R, Ahmed S, Islam N, et al. Epigallocatechin-3-gallate inhibits interleukin-1beta-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB. Arthritis Rheum 2002; 46(8): 2079–86PubMedCrossRef Singh R, Ahmed S, Islam N, et al. Epigallocatechin-3-gallate inhibits interleukin-1beta-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB. Arthritis Rheum 2002; 46(8): 2079–86PubMedCrossRef
102.
go back to reference Adcocks C, Collin P, Buttle DJ. Catechins from green tea (Camellia sinensis) inhibit bovine and human cartilage proteoglycan and type II collagen degradation in vitro. J Nutr 2002; 132(3): 341–6PubMed Adcocks C, Collin P, Buttle DJ. Catechins from green tea (Camellia sinensis) inhibit bovine and human cartilage proteoglycan and type II collagen degradation in vitro. J Nutr 2002; 132(3): 341–6PubMed
103.
go back to reference Awang D. Ginger. Can Pharm J 1992; 3: 309–11 Awang D. Ginger. Can Pharm J 1992; 3: 309–11
104.
go back to reference Schulick P. Ginger, common spice and wonder drug. 3rd ed. Brattleboro (VT): Herbal Free Press Ltd, 1996 Schulick P. Ginger, common spice and wonder drug. 3rd ed. Brattleboro (VT): Herbal Free Press Ltd, 1996
105.
go back to reference Kiuchi F, Iwakami S, Shibuya M, et al. Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chem Pharm Bull (Tokyo) 1992; 40(2): 387–91CrossRef Kiuchi F, Iwakami S, Shibuya M, et al. Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chem Pharm Bull (Tokyo) 1992; 40(2): 387–91CrossRef
106.
go back to reference Altman RD, Marcussen KC. Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum 2001; 44(11): 2531–8PubMedCrossRef Altman RD, Marcussen KC. Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum 2001; 44(11): 2531–8PubMedCrossRef
108.
go back to reference Fleisch H, Russell RGG, Bisaz S, et al. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo [abstract]. Calcif Tissue Res 1968; 2: 10ACrossRef Fleisch H, Russell RGG, Bisaz S, et al. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo [abstract]. Calcif Tissue Res 1968; 2: 10ACrossRef
109.
go back to reference Spector TD. Bisphosphonates: potential therapeutic agents for disease modification in osteoarthritis. Aging Clin Exp Res 2003; 15(5): 413–8PubMed Spector TD. Bisphosphonates: potential therapeutic agents for disease modification in osteoarthritis. Aging Clin Exp Res 2003; 15(5): 413–8PubMed
110.
go back to reference Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993; 92(6): 2577–86PubMedCrossRef Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993; 92(6): 2577–86PubMedCrossRef
111.
go back to reference Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79(6): 1693–700PubMedCrossRef Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79(6): 1693–700PubMedCrossRef
112.
go back to reference Felson DT, Chaisson CE, Hill CL, et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med 2001; 134(7): 541–9PubMed Felson DT, Chaisson CE, Hill CL, et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med 2001; 134(7): 541–9PubMed
113.
go back to reference Zhang Y, Hannan MT, Chaisson CE, et al. Bone mineral density and risk of incident and progressive radiographic knee osteoarthritis in women: the Framingham Study. J Rheumatol 2000; 27(4): 1032–7PubMed Zhang Y, Hannan MT, Chaisson CE, et al. Bone mineral density and risk of incident and progressive radiographic knee osteoarthritis in women: the Framingham Study. J Rheumatol 2000; 27(4): 1032–7PubMed
114.
go back to reference Grimes DA, Lobo RA. Perspectives on the Women’s Health Initiative trial of hormone replacement therapy. Obstet Gynecol 2002; 100(6): 1344–53PubMedCrossRef Grimes DA, Lobo RA. Perspectives on the Women’s Health Initiative trial of hormone replacement therapy. Obstet Gynecol 2002; 100(6): 1344–53PubMedCrossRef
115.
go back to reference Beary III JF. Joint structure modification in osteoarthritis: development of SMOAD drugs. Curr Rheumatol Rep 2001; 3(6): 506–12PubMedCrossRef Beary III JF. Joint structure modification in osteoarthritis: development of SMOAD drugs. Curr Rheumatol Rep 2001; 3(6): 506–12PubMedCrossRef
116.
go back to reference Murphy G, Knauper V, Atkinson S, et al. Matrix metal-loproteinases in arthritic disease. Arthritis Res 2002; 4Suppl. 3: S39–49PubMedCrossRef Murphy G, Knauper V, Atkinson S, et al. Matrix metal-loproteinases in arthritic disease. Arthritis Res 2002; 4Suppl. 3: S39–49PubMedCrossRef
117.
go back to reference Borden P, Heller RA. Transcriptional control of matrix metal-loproteinases and the tissue inhibitors of matrix metal-loproteinases. Crit Rev Eukaryot Gene Expr 1997; 7(1–2): 159–78PubMedCrossRef Borden P, Heller RA. Transcriptional control of matrix metal-loproteinases and the tissue inhibitors of matrix metal-loproteinases. Crit Rev Eukaryot Gene Expr 1997; 7(1–2): 159–78PubMedCrossRef
118.
go back to reference Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis: easier said than done? Arthritis Rheum 1994; 37(8): 1115–26PubMedCrossRef Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis: easier said than done? Arthritis Rheum 1994; 37(8): 1115–26PubMedCrossRef
119.
go back to reference Greenwald RA. Treatment of destructive arthritic disorders with MMP inhibitors: potential role of tetracyclines. Ann N Y Acad Sci 1994; 732: 181–98PubMedCrossRef Greenwald RA. Treatment of destructive arthritic disorders with MMP inhibitors: potential role of tetracyclines. Ann N Y Acad Sci 1994; 732: 181–98PubMedCrossRef
120.
go back to reference Yu Jr LP, Smith Jr GN, Brandt KD, et al. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992; 35(10): 1150–9PubMedCrossRef Yu Jr LP, Smith Jr GN, Brandt KD, et al. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992; 35(10): 1150–9PubMedCrossRef
121.
go back to reference Brandt KD. Modification by oral doxycycline administration of articular cartilage breakdown in osteoarthritis. J Rheumatol Suppl 1995; 43: 149–51PubMed Brandt KD. Modification by oral doxycycline administration of articular cartilage breakdown in osteoarthritis. J Rheumatol Suppl 1995; 43: 149–51PubMed
122.
go back to reference Caron JP, Fernandes JC, Martel-Pelletier J, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression. Arthritis Rheum 1996; 39(9): 1535–44PubMedCrossRef Caron JP, Fernandes JC, Martel-Pelletier J, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression. Arthritis Rheum 1996; 39(9): 1535–44PubMedCrossRef
123.
go back to reference van de Loo AA, Arntz OJ, Bakker AC, et al. Role of interleukin 1 in antigen-induced exacerbations of murine arthritis. Am J Pathol 1995; 146(1): 239–49PubMed van de Loo AA, Arntz OJ, Bakker AC, et al. Role of interleukin 1 in antigen-induced exacerbations of murine arthritis. Am J Pathol 1995; 146(1): 239–49PubMed
124.
go back to reference Saha N, Moldovan F, Tardif G, et al. Interleukin-1beta-converting enzyme/caspase-1 in human osteoarthritic tissues: localization and role in the maturation of interleukin-1beta and interleukin-18. Arthritis Rheum 1999; 42(8): 1577–87PubMedCrossRef Saha N, Moldovan F, Tardif G, et al. Interleukin-1beta-converting enzyme/caspase-1 in human osteoarthritic tissues: localization and role in the maturation of interleukin-1beta and interleukin-18. Arthritis Rheum 1999; 42(8): 1577–87PubMedCrossRef
125.
go back to reference Rudolphi K, Gerwin N, Verzijl N, et al. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 2003 Oct; 11(10): 738–46PubMedCrossRef Rudolphi K, Gerwin N, Verzijl N, et al. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 2003 Oct; 11(10): 738–46PubMedCrossRef
126.
go back to reference Amin AR, Abramson SB. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol 1998; 10(3): 263–8PubMedCrossRef Amin AR, Abramson SB. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol 1998; 10(3): 263–8PubMedCrossRef
127.
go back to reference Hirai Y, Migita K, Honda S, et al. Effects of nitric oxide on matrix metalloproteinase-2 production by rheumatoid synovial cells. Life Sci 2001; 68(8): 913–20PubMedCrossRef Hirai Y, Migita K, Honda S, et al. Effects of nitric oxide on matrix metalloproteinase-2 production by rheumatoid synovial cells. Life Sci 2001; 68(8): 913–20PubMedCrossRef
128.
go back to reference Clancy RM, Abramson SB, Kohne C, et al. Nitric oxide attenuates cellular hexose monophosphate shunt response to oxidants in articular chondrocytes and acts to promote oxidant injury. J Cell Physiol 1997; 172(2): 183–91PubMedCrossRef Clancy RM, Abramson SB, Kohne C, et al. Nitric oxide attenuates cellular hexose monophosphate shunt response to oxidants in articular chondrocytes and acts to promote oxidant injury. J Cell Physiol 1997; 172(2): 183–91PubMedCrossRef
129.
go back to reference Pelletier JP, Jovanovic DV, Lascau-Coman V, et al. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. J Rheumatol 1999; 26(9): 2002–14PubMed Pelletier JP, Jovanovic DV, Lascau-Coman V, et al. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. J Rheumatol 1999; 26(9): 2002–14PubMed
130.
go back to reference Pelletier JP, Jovanovic D, Fernandes JC, et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998; 41(7): 1275–86PubMedCrossRef Pelletier JP, Jovanovic D, Fernandes JC, et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998; 41(7): 1275–86PubMedCrossRef
131.
go back to reference van den Berg WB, van de Loo F, Joosten LA, et al. Animal models of arthritis in NOS2-deficient mice. Osteoarthritis Cartilage 1999; 7(4): 413–5PubMedCrossRef van den Berg WB, van de Loo F, Joosten LA, et al. Animal models of arthritis in NOS2-deficient mice. Osteoarthritis Cartilage 1999; 7(4): 413–5PubMedCrossRef
133.
go back to reference Bandara GM, Mueller GM, Galea-Lauri J, et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A 1993; 90(22): 10764–8PubMedCrossRef Bandara GM, Mueller GM, Galea-Lauri J, et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A 1993; 90(22): 10764–8PubMedCrossRef
134.
go back to reference Mi Z, Ghivizzani SC, Lechman ER, et al. Adenovirus-mediated gene transfer of insulin-like growth factor 1 stimulates proteoglycan synthesis in rabbit joints. Arthritis Rheum 2000; 43(11): 2563–70PubMedCrossRef Mi Z, Ghivizzani SC, Lechman ER, et al. Adenovirus-mediated gene transfer of insulin-like growth factor 1 stimulates proteoglycan synthesis in rabbit joints. Arthritis Rheum 2000; 43(11): 2563–70PubMedCrossRef
135.
go back to reference Kang R, Marui T, Ghivizzani SC, et al. Ex vivo gene transfer to chondrocytes in full-thickness articular cartilage defects: a feasibility study. Osteoarthritis Cartilage 1997; 5(2): 139–43PubMedCrossRef Kang R, Marui T, Ghivizzani SC, et al. Ex vivo gene transfer to chondrocytes in full-thickness articular cartilage defects: a feasibility study. Osteoarthritis Cartilage 1997; 5(2): 139–43PubMedCrossRef
136.
go back to reference Evans CH, Ghivizzani SC, Herndon JH, et al. Clinical trials in the gene therapy of arthritis. Clin Orthop 2000; (379 Suppl.): S300–7 Evans CH, Ghivizzani SC, Herndon JH, et al. Clinical trials in the gene therapy of arthritis. Clin Orthop 2000; (379 Suppl.): S300–7
Metadata
Title
Disease-Modifying Therapies for Osteoarthritis
Current Status
Authors
Marc Fajardo
Dr Paul E. Di Cesare
Publication date
01-02-2005
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 2/2005
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200522020-00005

Other articles of this Issue 2/2005

Drugs & Aging 2/2005 Go to the issue

Review Article

Poststroke Aphasia

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine